An independent market-research firm that focuses on veterinary products’ market share and product sales tracking has measured a dramatic increase in the MLV pasteurella combination vaccine category.

According to Market Dynamics Inc., the MLV pasteurella combination vaccine category has grown more than 60 percent from 2001 to 2006 in the United States. These MLV respiratory pasteurella combination products now represent a $20M-plus vaccine category that includes products like Intervet’s Vista Once SQ, which offers a unique avirulent live Pasteurella multocida and Mannheimia haemolytica and five-way viral combination in a single, subcutaneous dose.

“Launched in late 2005, Vista Once SQ captured the No. 1 position in the MLV pasteurella combination vaccine category in its first year,” says Jeff Baxter, Intervet marketing manager for cattle vaccines. “Vista Once SQ currently maintains an industry-leading position with 47 percent of the category market share. Producers and veterinarians appreciate the advantage of getting the most complete protection with the convenience of one injection, while consumers benefit with the BQA benefits of a single, one-time subcutaneous injection. It’s a win-win.”

Producing quality beef

Another reason for the rapid adoption of these combination vaccines is the increasing awareness of and compliance with BQA recommendations, Baxter says. The combination vaccine eliminates the need for administering an additional injection, which reduces stress on the animal and benefits meat quality.

Source: Dairy Network